keyword
MENU ▼
Read by QxMD icon Read
search

Plasmablastic lymphoma

keyword
https://www.readbyqxmd.com/read/29105119/lymphoproliferative-disorders-with-concurrent-hhv8-and-ebv-infection-beyond-primary-effusion-lymphoma-and-germinotropic-lymphoproliferative-disorder
#1
Wei Wang, Rashmi Kanagal-Shamanna, Jeffrey L Medeiros
AIMS: Lymphoproliferative disorders (LPD) characterized by human herpesvirus 8 (HHV8) and Epstein-Barr virus (EBV) infection are rare and two entities are included in the World and Health Organization classification: primary effusion lymphoma (PEL) and germinotropic LPD. These two entities have very different clinicopathological presentations and prognosis. Here we describe two cases of HHV8-positive, EBV-positive lymphoma with clinicopathological features that are not consistent with either PEL or germinotropic LPD...
November 3, 2017: Histopathology
https://www.readbyqxmd.com/read/29090101/plasmablastic-lymphoma-case-report-of-prolonged-survival-of-an-advanced-human-immunodeficiency-patient-and-literature-review
#2
Hind Rafei, Ehab El-Bahesh, Antoine Finianos, Min-Ling L Liu, Geraldine P Schechter
Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses...
2017: Case Reports in Hematology
https://www.readbyqxmd.com/read/29081245/primary-cutaneous-plasmablastic-lymphoma-in-an-immunocompetent-patient-is-it-associated-with-an-indolent-course
#3
Brady E Beltran, Pilar Quiñones, Gadwyn Sanchez, Antonio Paredes, Celia Moises, Esther Cotrina, Carlos A Torres-Cabala, Roberto N Miranda, Jorge J Castillo
No abstract text is available yet for this article.
October 30, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29019447/survival-of-patients-with-cd20-negative-variants-of-large-b-cell-lymphoma-an-analysis-of-the-national-cancer-data-base
#4
Lindor Qunaj, Jorge J Castillo, Adam J Olszewski
Using records from the National Cancer Data Base, we studied overall survival of CD20-negative variants of diffuse large B-cell lymphoma (DLBCL): primary effusion (PEL, N = 228), plasmablastic (PBL, N = 481), ALK-positive large B-cell (ALK + LBLC, N = 15), and human herpesvirus-8-positive DLBCL (HHV8 + DLBCL, N = 77). Three-year survival was 27% for PEL, 40% for PBL, 34% for ALK + LBCL, and 63% for HHV8 + DLBCL. Compared with unspecified DLBCL, and adjusting for clinical characteristics (including the HIV status), survival was significantly worse for PEL (hazard ratio [HR], 1...
October 11, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28993364/durable-complete-remission-with-combination-chemotherapy-and-bortezomib-in-hiv-associated-plasmablastic-lymphoma
#5
Nivedita Arora, Arjun Gupta, Navid Sadeghi
Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum...
October 9, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28982264/de-novo-unclassifiable-cd20-negative-diffuse-large-b-cell-lymphoma-a-diagnostic-and-therapeutic-challenge
#6
Badr AbdullGaffar, Rania M Seliem
CD20-negative diffuse large B-cell lymphomas (DLBCLs) constitute a rare and heterogeneous group of aggressive lymphomas. Known well-documented variants include plasmablastic lymphomas, primary effusion lymphomas, anaplastic kinase-positive large B-cell lymphomas, and large B-cell lymphomas arising in human herpesvirus 8 (HHV8)-associated multicentric Castleman disease. They impose diagnostic challenges for pathologists and therapeutic confrontations for clinicians. CD20 loss in B-cell lymphomas is a well-known phenomenon after rituximab therapy...
October 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28963907/bortezomib-in-plasmablastic-lymphoma-a-glimpse-of-hope-for-a-hard-to-treat-disease
#7
REVIEW
Thomas A Guerrero-Garcia, Renzo J Mogollon, Jorge J Castillo
Plasmablastic lymphoma (PBL) is a rare and hard to treat disease. With current standard chemotherapeutic regimens, PBL is associated with a median overall survival of 12-15 months. We performed a systematic review of the literature through March 31, 2017 looking for patients with a diagnosis of PBL who were treated with bortezomib, alone or in combination. We identified 21 patients, of which 11 received bortezomib in the frontline setting and 10 received bortezomib in the relapsed setting. Eleven patients were HIV-positive and 10 were HIV-negative...
November 2017: Leukemia Research
https://www.readbyqxmd.com/read/28929004/intraocular-plasmablastic-lymphoma-in-a-hiv-patient
#8
Carolline Fontes Alves Mariano, Glauce Lunardelli Trevisan, Antonio Augusto Velasco E Cruz, Fernando Chahud
Plasmablastic lymphoma (PBL) is a rare B-cell lymphoma occurring mainly in HIV patients. The tumor frequently involves extranodal sites such as the oral cavity, nasal cavity, gastrointestinal tract, skin, and lungs. The neoplastic cells are characterized by a plasmablastic appearance and typical immunophenotype that indicates plasma cell differentiation. Herein, we report a case of intraocular involvement by plasmablastic lymphoma in a HIV patient with a long history of cytomegalovirus retinitis and loss of vision...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/28916317/presence-of-human-herpesvirus-8-hhv-8-dna-sequences-in-patients-with-lymphoproliferative-diseases-and-chronic-blood-disorders
#9
Hossein Keyvani, Mohammad Hadi Karbalaie Niya, Maryam Esghaei, Farah Bokharaei-Salim, Seyed Hamid Reza Monavari
OBJECTIVE: Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi's sarcoma (KS), but it has also been associated with different hematologic malignancies, including plasmablastic lymphoma, Multicentric Castleman's disease (MCD), primary effusion lymphoma (PEL) and various atypical lymphoproliferative disorders. Patients with underlying lymphoproliferative diseases and chronic blood disorders who become infected with this virus are at risk for human malignancies. This small study reported the frequency of human herpesvirus 8 in 81 Iranian patients with lymphoproliferative disorders for estimation of possible factors affecting malignancy...
October 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28913874/an-algorithmic-approach-to-diagnose-haematolymphoid-neoplasms-in-effusion-by-combining-morphology-immunohistochemistry-and-molecular-cytogenetics
#10
L Chen, J S Zhang, D G Liu, D Cui, Z L Meng
OBJECTIVE: There are limited studies of cytology diagnosis of haematopoietic and lymphoid tumours in serosal effusion except for occasional case reports. We would like to demonstrate an algorithmic approach for accurate diagnosis, especially in patients without previous history. METHODS: We reviewed 36 cases of lymphoma diagnosed in serosal effusion following an algorithmic approach. Suspected tumour cells were classified into small, intermediate and large sizes and two characteristic forms of plasmacytoid and Reed Sternberg-like on smears (step 1), followed by utilising panels of immunohistochemical markers and Epstein-Barr encoding region in situ hybridisation on cell blocks (step 2)...
September 15, 2017: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/28893942/kaposi-sarcoma-herpesvirus-pathogenesis
#11
REVIEW
Giuseppe Mariggiò, Sandra Koch, Thomas F Schulz
Kaposi sarcoma herpesvirus (KSHV), taxonomical name human gammaherpesvirus 8, is a phylogenetically old human virus that co-evolved with human populations, but is now only common (seroprevalence greater than 10%) in sub-Saharan Africa, around the Mediterranean Sea, parts of South America and in a few ethnic communities. KSHV causes three human malignancies, Kaposi sarcoma, primary effusion lymphoma, and many cases of the plasmablastic form of multicentric Castleman's disease (MCD) as well as occasional cases of plasmablastic lymphoma arising from MCD; it has also been linked to rare cases of bone marrow failure and hepatitis...
October 19, 2017: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
https://www.readbyqxmd.com/read/28878909/a-rare-case-of-epstein-barr-virus-related-plasmacytoma-involving-maxillary-sinus-mucosa
#12
Julie D Gibbs, Marino E Leon, Kenia Liu, Johnny Nguyen, Ling Zhang
Extramedullary plasmacytomas, Epstein-Bar virus (EBV) associated, are rarely encountered and usually have a fairly good clinical outcome. EBV+ plasmacytoma may cause a diagnostic dilemma as it phenotypically resembles an aggressive plasmablastic lymphoma (PBL). Herein, we report a unique case with maxillary EBV+ plasmacytoma from a 76-year-old immunocompetent individual.
September 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28860565/interleukin-6-dependent-growth-in-a-newly-established-plasmablastic-lymphoma-cell-line-and-its-therapeutic-targets
#13
Sohtaro Mine, Tsunekazu Hishima, Akihiko Suganuma, Hitomi Fukumoto, Yuko Sato, Michiyo Kataoka, Tsuyoshi Sekizuka, Makoto Kuroda, Tadaki Suzuki, Hideki Hasegawa, Masashi Fukayama, Harutaka Katano
Plasmablastic lymphoma (PBL) is a rare, highly aggressive subtype of non-Hodgkin lymphoma with plasma-cell differentiation occurring typically in immune-suppressed patients such as those with AIDS. This study reports the establishment and characterization of a new cell line, PBL-1, derived from a patient with AIDS-associated PBL. Morphological assessment of PBL-1 indicated plasma-cell differentiation with a CD20(-) CD38(+) CD138(+) immunophenotype and IgH/c-myc translocation. The cell line harbours Epstein-Barr virus, but a 52...
August 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28825948/11c-methionine-avid-plasmablastic-lymphoma
#14
Salvatore Annunziata, Annarosa Cuccaro, Carmelo Caldarella, Lucia Leccisotti, Stefan Hohaus
A 73-year-old woman had a diagnosis of a plasmablastic lymphoma by the excision of the right parotid gland. Two years after the diagnosis, the patient underwent a whole-body C-methionine PET/CT in order to evaluate the amino acid avidity of a scalp metastasis and for plasmablastic lymphoma restaging. C-methionine uptake was detected in the scalp, in several bone sites, and in the cricoid cartilage. Plasmablastic lymphoma is a subtype of B-cell lymphoma with an aggressive behavior and a poor prognosis. C-methionine appears to be a promising tracer for paraprotein-producing neoplasms...
August 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28782668/plasmablastic-lymphoma-in-a-patient-with-crohn-s-disease-after-extensive-immunosuppressive-therapy
#15
Gaurav Ghosh, Vinita Jacob, David Wan
No abstract text is available yet for this article.
August 4, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28766549/-analysis-of-inpatient-care-for-hiv-positive-patients-with-malignant-lymphomas-and-hepatitis-over-5-years-2011-2015-at-the-a-s-loginov-moscow-clinical-research-center-moscow-healthcare-department
#16
A V Pivnik, M V Tumanova, A V Chistyakova, G A Dudina, M G Dubnitskaya, O V Mukhin, E P Sergeeva
The authors give their own data in the first Russian publication on 170 patients with lymphomas and hepatitis concurrent with HIV infection, on the distribution of therapy regimens by nosological entities and the number of deaths. Conventional protocols and programs were used for diagnosis and treatment. All the patients received highly active antiretroviral therapy. Lymphoma was treated according to the conventional programs using rituximab in people without hepatitis B. Aggressive lymphomas, such as diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma, were identified in most patients...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28746329/plasmablastic-lymphoma
#17
S Bhusal, B Acharya, S Chapagain
Plasmablastic lymphoma is a rare and aggressive lymphoma reported to be commonly associated with immunodeficiency state. It possesses a challenge to the clinician owing it aggressiveness and poor prognosis. No standard of care treatment is available for the disease. Here we report a case of an immunocompetant 67 years female who is unique in her presentation as she did not have any of the conventional clinical features and had a history of urothelial carcinoma three months back.
April 2017: JNMA; Journal of the Nepal Medical Association
https://www.readbyqxmd.com/read/28702410/plasmablastic-lymphoma-in-immunocompetent-and-in-immunocompromised-patients-experience-at-a-regional-cancer-centre-in-india
#18
A H Rudresha, K C Lakshmaiah, Ankit Agarwal, K Govind Babu, D Loknatha, Linu Abraham Jacob, Suresh Babu, K N Lokesh, L K Rajeev
INTRODUCTION: Plasmablastic lymphoma (PBL) is a rare lymphoma associated with immunosuppression. It is strongly associated with immunosuppression (human immunodeficiency virus [HIV]) and often occurs within the oral cavity. PBL is also seen in patients receiving immunosuppressive therapy; however, despite its predisposition for the immunocompromised patients, PBL has been diagnosed in immunocompetent patients. AIM: This study aims to prognostic factors and outcome of PBL in immunocompromised and in immunocompetent patients...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28701369/synergistic-cooperation-and-crosstalk-between-myd88-l265p-and-mutations-that-dysregulate-cd79b-and-surface-igm
#19
James Q Wang, Yogesh S Jeelall, Peter Humburg, Emma L Batchelor, Sarp M Kaya, Hee Min Yoo, Christopher C Goodnow, Keisuke Horikawa
CD79B and MYD88 mutations are frequently and simultaneously detected in B cell malignancies. It is not known if these mutations cooperate or how crosstalk occurs. Here we analyze the consequences of CD79B and MYD88(L265P) mutations individually and combined in normal activated mouse B lymphocytes. CD79B mutations alone increased surface IgM but did not enhance B cell survival, proliferation, or altered NF-κB responsive markers. Conversely, B cells expressing MYD88(L265P) decreased surface IgM coupled with accumulation of endoglycosidase H-sensitive IgM intracellularly, resembling the trafficking block in anergic B cells repeatedly stimulated by self-antigen...
September 4, 2017: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28700895/plasmablastic-lymphoma-presenting-as-exophytic-skin-lesions
#20
Riad El Fakih, Muhamad Almahayni, Maamoun Alsermani
No abstract text is available yet for this article.
July 5, 2017: Hematology/oncology and Stem Cell Therapy
keyword
keyword
16328
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"